185 related articles for article (PubMed ID: 37557012)
1. The roles of epigenetic regulation in cholangiocarcinogenesis.
Zhong B; Liao Q; Wang X; Wang X; Zhang J
Biomed Pharmacother; 2023 Oct; 166():115290. PubMed ID: 37557012
[TBL] [Abstract][Full Text] [Related]
2. The pathways of genetic transformation in cholangiocarcinogenesis.
Serafini FM; Radvinsky D
Cancer Genet; 2016 Dec; 209(12):554-558. PubMed ID: 27720541
[TBL] [Abstract][Full Text] [Related]
3. Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis.
Goeppert B; Stichel D; Toth R; Fritzsche S; Loeffler MA; Schlitter AM; Neumann O; Assenov Y; Vogel MN; Mehrabi A; Hoffmann K; Köhler B; Springfeld C; Weichenhan D; Plass C; Esposito I; Schirmacher P; von Deimling A; Roessler S
Gut; 2022 Feb; 71(2):391-401. PubMed ID: 33468537
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic regulation in the carcinogenesis of cholangiocarcinoma.
Chiang NJ; Shan YS; Hung WC; Chen LT
Int J Biochem Cell Biol; 2015 Oct; 67():110-4. PubMed ID: 26100596
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways.
Kongpetch S; Jusakul A; Ong CK; Lim WK; Rozen SG; Tan P; Teh BT
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):233-44. PubMed ID: 25966424
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic alterations in cholangiocarcinoma-sustained IL-6/STAT3 signaling in cholangio- carcinoma due to SOCS3 epigenetic silencing.
Isomoto H
Digestion; 2009; 79 Suppl 1():2-8. PubMed ID: 19153483
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic alterations associated with cholangiocarcinoma (review).
Isomoto H
Oncol Rep; 2009 Aug; 22(2):227-32. PubMed ID: 19578760
[TBL] [Abstract][Full Text] [Related]
8. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.
Colyn L; Alvarez-Sola G; Latasa MU; Uriarte I; Herranz JM; Arechederra M; Vlachogiannis G; Rae C; Pineda-Lucena A; Casadei-Gardini A; Pedica F; Aldrighetti L; López-López A; López-Gonzálvez A; Barbas C; Ciordia S; Van Liempd SM; Falcón-Pérez JM; Urman J; Sangro B; Vicent S; Iraburu MJ; Prosper F; Nelson LJ; Banales JM; Martinez-Chantar ML; Marin JJG; Braconi C; Trautwein C; Corrales FJ; Cubero FJ; Berasain C; Fernandez-Barrena MG; Avila MA
J Exp Clin Cancer Res; 2022 May; 41(1):183. PubMed ID: 35619118
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanism of cholangiocarcinoma carcinogenesis.
Maemura K; Natsugoe S; Takao S
J Hepatobiliary Pancreat Sci; 2014 Oct; 21(10):754-60. PubMed ID: 24895231
[TBL] [Abstract][Full Text] [Related]
10. Epigenome dysregulation in cholangiocarcinoma.
O'Rourke CJ; Munoz-Garrido P; Aguayo EL; Andersen JB
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1423-1434. PubMed ID: 28645654
[TBL] [Abstract][Full Text] [Related]
11. Genetic and molecular abnormalities in cholangiocarcinogenesis.
Hassid VJ; Orlando FA; Awad ZT; Tan D; Khoury T; Ahmed BH; Alrawi SJ
Anticancer Res; 2009 Apr; 29(4):1151-6. PubMed ID: 19414358
[TBL] [Abstract][Full Text] [Related]
12. Involvement of Epigenomic Factors in Bile Duct Cancer.
Rogalska-Taranta M; Andersen JB
Semin Liver Dis; 2022 May; 42(2):202-211. PubMed ID: 35738258
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathogenesis of cholangiocarcinoma.
Rizvi S; Gores GJ
Dig Dis; 2014; 32(5):564-9. PubMed ID: 25034289
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation: Impact on Regulation of Notch Pathway.
Kwon H; Song K; Han C; Zhang J; Lu L; Chen W; Wu T
Am J Pathol; 2017 Oct; 187(10):2288-2299. PubMed ID: 28923203
[TBL] [Abstract][Full Text] [Related]
15. Long noncoding RNA ANRIL promotes the malignant progression of cholangiocarcinoma by epigenetically repressing ERRFI1 expression.
Yu Y; Chen Q; Zhang X; Yang J; Lin K; Ji C; Xu A; Yang L; Miao L
Cancer Sci; 2020 Jul; 111(7):2297-2309. PubMed ID: 32378752
[TBL] [Abstract][Full Text] [Related]
16. Emerging roles of long noncoding RNAs in cholangiocarcinoma: Advances and challenges.
Yang Y; Deng X; Li Q; Wang F; Miao L; Jiang Q
Cancer Commun (Lond); 2020 Dec; 40(12):655-680. PubMed ID: 33142045
[TBL] [Abstract][Full Text] [Related]
17. Targeting polycomb repressor complex 2-mediated bivalent promoter epigenetic silencing of secreted frizzled-related protein 1 inhibits cholangiocarcinoma progression.
Wu G; Wang Q; Wang D; Xiong F; Liu W; Chen J; Wang B; Huang W; Wang X; Chen Y
Clin Transl Med; 2023 Dec; 13(12):e1502. PubMed ID: 38050190
[TBL] [Abstract][Full Text] [Related]
18. Circular RNAs in cholangiocarcinoma.
Liao W; Feng Q; Liu H; Du J; Chen X; Zeng Y
Cancer Lett; 2023 Jan; 553():215980. PubMed ID: 36336149
[TBL] [Abstract][Full Text] [Related]
19. Genetic and epigenetic changes associated with cholangiocarcinoma: from DNA methylation to microRNAs.
Stutes M; Tran S; DeMorrow S
World J Gastroenterol; 2007 Dec; 13(48):6465-9. PubMed ID: 18161915
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-27a-3p targets FoxO signalling to induce tumour-like phenotypes in bile duct cells.
Duwe L; Munoz-Garrido P; Lewinska M; Lafuente-Barquero J; Satriano L; Høgdall D; Taranta A; Nielsen BS; Ghazal A; Matter MS; Banales JM; Aldana BI; Gao YT; Marquardt JU; Roberts LR; Oliveira RC; Koshiol J; O'Rourke CJ; Andersen JB
J Hepatol; 2023 Feb; 78(2):364-375. PubMed ID: 36848245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
